Vinati Organics Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nrtnd5d87zgxcxlaljfojx7e.pdf

Key Takeaways


ATBS: The Volume Growth Anchor

Vinati Mutreja: "When we dig oil out of the oil well, they realized that the more ATBS they put in the polymer, the more efficient it becomes then they're able to extract more oil."

Antioxidants: The High-Growth Second Leg

Vinati Mutreja: "See even presently -- at present also, my AO plant is running at less than 50%, about 50% capacity. So I expect to increase the capacity utilization to 90% over the next 2 years."

VOPL: The New Subsidiary Turns the Corner


Portfolio Mix & Market Shifts


Financial Guardrails

Vinati Mutreja: "I think over a long term period of 3 to 5 years, 26% - 27% EBITDA margin is what is sustainable in a B2B manufacturing business specialty chemical business."

Guidance & Commitments

CommitmentSpecificsTimeline
ATBS growthContinued double-digit growthFY26
ATBS Phase 1 capacity expansionCompletion, taking capacity from 40,000 to 60,000 tonsJune 2025
ATBS Phase 2 capacity expansionOn stream~June 2026 (one year after Phase 1)
ATBS capacity utilizationAdded capacity fully utilizedOver 3 years from completion
AO capacity utilizationIncrease from ~50% to 90%Over the next 2 years
VOPL revenueINR100-odd crores at ~20% capacity utilizationFY26
VOPL new product introductionsAnisole, 4-MAP, TAA, PTAPQ2 and Q3 FY26
Butyl phenols and antioxidants revenueINR800-850 croresFY26
EBITDA margin26%-27%FY26
Revenue CAGR20%Over the next 3 years
Next leg of capex announcementContingent on successful trials of 3-4 new R&D productsIn coming quarters
FY26 capexINR360-odd croresFY26

Key Metrics

MetricQ4 FY25
Consolidated net income (FY25)₹2,292 cr, +18% YoY from ₹1,939 cr
Consolidated EBITDA (FY25)₹625 cr, +23% YoY from ₹509 cr
Consolidated PAT (FY25)₹405 cr, +25% YoY from ₹323 cr
ATBS segment growth (FY25)30%, driven almost entirely by volume expansion
ATBS global market share60-65%, steady
Butyl phenol segment growth (FY25)26%
IBB segment growth (FY25)-27% YoY
Antioxidants revenue growth (FY25)70%
Capex incurred (FY25)~₹400 cr, including investments in VOPL
Capex planned (FY26)~₹360 cr
Revenue CAGR guidance (next 3 years)20%
EBITDA margin guidance (long-term)26-27%, excluding other income
VOPL revenue guidance (FY26)~₹100 cr
Butyl phenols + antioxidants combined revenue (FY25)₹600 cr
Butyl phenols + antioxidants combined revenue guidance (FY26)₹800-850 cr, all growth from antioxidants
ATBS capacity expansion Phase 125-30% increase, on stream June 2025
ATBS capex budget₹300 cr
VOPL total capex~₹500 cr, with ~₹250 cr yet to be done
VOPL FY25 loss₹12 cr depreciation plus ₹4 cr production and expenses
Revenue mix: ATBS~35%
Revenue mix: IB and HP-MTBE and other IB derivatives~15%
Revenue mix: IBB~11%
Revenue mix: Butyl phenol15%
Revenue mix: Antioxidants10%
Revenue mix: Other products15%
Export share55%, down from 70% three to four years ago
Solar capacity32.5 MW plant
Capital work in progress (as of March 2025)₹438 cr
Net fixed assets (FY25)₹1,723 cr, up ~₹225-235 cr YoY
ATBS demand split (current)One-third each: oil and gas, water treatment, other applications
ATBS demand split (forward outlook)Oil and gas 40-45%, other applications 50-55%
MEHQ captive consumption (once BHA fully commercialized)~30% of total production
AO plant capacity utilization (current)~50%
AO revenue (FY24)~₹120 cr
AO revenue (FY25)~₹210 cr+